Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
CanSino Biologics Inc
Chengdu Olymvax Biopharmaceuticals Inc
Chongqing Zhifei Biological Products Co Ltd
Jiangsu Kunli Biopharmaceutical Co Ltd
LG Chem Ltd
Liaoning Cheng Da Biotechnology Co Ltd
Lineus Bioscience Inc
Matis BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Pfizer Inc
Serum Institute of India Pvt Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd
Meningitis - Drug Profiles
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
Product Description
Mechanism Of Action
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
amphotericin B - Drug Profile
Product Description
Mechanism Of Action
APX-2039 - Drug Profile
Product Description
Mechanism Of Action
CSB-015 - Drug Profile
Product Description
Mechanism Of Action
flucytosine - Drug Profile
Product Description
Mechanism Of Action
Haemophilus influenzae B vaccine - Drug Profile
Product Description
Mechanism Of Action
LBVD - Drug Profile
Product Description
Mechanism Of Action
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
meningitis vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A and C] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A, C] vaccine - Drug Profile
Product Description
Mechanism Of Action
meningococcal [serotypes A] vaccine - Drug Profile
Product Description
Mechanism Of Action
MYC-053 - Drug Profile
Product Description
Mechanism Of Action
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
pneumococcal [serotype 4, 6A] vaccine - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile
Product Description
Mechanism Of Action
VT-1598 - Drug Profile
Product Description
Mechanism Of Action
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Oct 23, 2022: Matis BioPharma to present new MAT2203 (oral amphotericin B) data during IDWeek 2022
Oct 21, 2022: Matis BioPharma announces positive interim data from the phase 2 ECT trial of MAT2203 for the treatment of cryptococcal meningitis, exceeding primary endpoint threshold; patient survival in all-oral cohort 4 regimen currently 90%
Oct 19, 2022: Matis BioPharma announces Infectious Diseases Society of America (IDSA) has selected the ECT phase 2 trial abstract of MAT2203 as its outstanding abstract and IDSA awardee for IDWeek 2022
Dec 16, 2021: Matis BioPharma announces unimous DSMB approval to progress into fourth and fil cohort of patients in the ECT Trial of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Sep 13, 2021: Matis BioPharma announces positive data in the ongoing ECT trial of MAT2203 (Oral Amphotericin B) for the treatment of cryptococcal meningitis, exceeding the prespecified primary endpoint threshold
Aug 16, 2021: Matis BioPharma announces issuance of U.S. patent protecting MAT2203 to treat or prevent cryptococcus infections
Oct 19, 2020: Matis BioPharma announces unimous DSMB approval to progress into second cohort of patients in the ECT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Aug 20, 2020: Matis BioPharma announces publication of results from phase 1 portion of the ECT study investigating safety and tolerability of MAT2203
Feb 19, 2020: Matis BioPharma announces DSMB approval to commence part 2 of ECT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis
Oct 14, 2019: Matis BioPharma initiates ECT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis
Oct 07, 2019: Matis BioPharma receives orphan drug desigtion from U.S. FDA for MAT2203 for the treatment of cryptococcosis
Jul 25, 2019: Matis BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Desigtions From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
Jun 03, 2019: Matis BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitatiol
May 28, 2019: Matis BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Jourl, mBio
May 01, 2019: Matis BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Meningitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Meningitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Meningitis - Pipeline by CanSino Biologics Inc, 2022
Meningitis - Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Meningitis - Pipeline by Jiangsu Kunli Biopharmaceutical Co Ltd, 2022
Meningitis - Pipeline by LG Chem Ltd, 2022
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022
Meningitis - Pipeline by Linnaeus Bioscience Inc, 2022
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, 2022
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Meningitis - Pipeline by Pfizer Inc, 2022
Meningitis - Pipeline by Serum Institute of India Pvt Ltd, 2022
Meningitis - Pipeline by TGV Therapeutics, 2022
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, 2022
Meningitis - Dormant Projects, 2022
Meningitis - Dormant Projects, 2022 (Contd..1)
Meningitis - Discontinued Products, 2022